Canada’s New PM Mark Carney, a Trump Critic, Faces Claims of Being Disconnected from Everyday Canadians

OTTAWA-Mark Carney, Canada's newly appointed Prime Minister and self-proclaimed 'globalist', wasted no time criticizing Donald Trump after winning the Liberal leadership race last week.In his acceptance speech, Carney stated that Canadian tariffs on the United States would remain until the U.S. demonstrates "respect," adding that Canadians "are always ready when…

ISIS Leader Killed in Iraq, Trump Says

Iraqi Prime Minister Mohammed Shia al-Sudani announced Friday the death of a senior leader within the Islamic State organization in Iraq and Syria.Al-Sudani's statement identified the leader as Abdallah Maki Mosleh al-Rifai, also known as Abu Khadija, and credited Iraqi national intelligence and U.S.-led coalition forces with the operation.The prime…

PayPal Versus Robinhood: A Fintech Battle

In the fast-paced world of financial technology, PayPal Holdings, Inc. (NASDAQ:PYPL) and Robinhood Markets, Inc. (NASDAQ:HOOD) are two prominent players. With the increasing popularity of digital transactions and investment platforms, these companies have established themselves as leaders in innovation and expansion. This article examines their business strategies, financial stability, and…

S&P 500 Dividend Stocks Worth Considering

` tags. Investors are constantly seeking superior stocks that promise consistent returns coupled with the possibility of expansion. Dividend stocks listed in the S&P 500 are particularly appealing because they offer both income potential and the chance for capital growth. This article will examine three outstanding S&P 500 dividend stocks…

DocuSign Stock Surges on AI Platform Success

Following better-than-expected quarterly results, the electronic signature technology company DocuSign witnessed a surge in its stock price. The NASDAQ-listed company (DOCU) credited the success to the widespread acceptance of its new AI platform. This platform aims to simplify document management, providing businesses with more efficient workflows and better security. Integrating…

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease

BETHESDA, MD, Mar 14, 2025 - (ACN Newswire via SeaPRwire.com) - Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the dosing of the first participant with Parkinson’s disease (PD)…